You are here

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

125em; text-align: left; ">Blood. 2012 Feb 27. [Epub ahead of print] - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini CB, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N,Leip E, Kelly V, Brummendorf TH.

Source

Winship Cancer Institute of Emory University, Atlanta, GA, United States;

http://www.ncbi.nlm.nih.gov/pubmed/22371878